Clinical trials - Press Releases

Date	Title	Company
11-Oct-2021	AZD7442 reduced risk of developing severe COVID-19 or death in TACKLE Phase III outpatient treatment trial	AstraZeneca
08-Oct-2021	AMZELL BV receives FDA Special Protocol Assessment for Phase 3 trial of innovative injectable treatment for infantile epileptic disease	AMZELL BV
07-Oct-2021	New Elsevier report highlights progress towards disease-modifying treatments for pancreatitis	Elsevier
06-Oct-2021	PEP-Therapy and Institut Curie announce first patients dosed in Phase I clinical trial of PEP-010 for the treatment of advanced solid tumors	PEP-Therapy
05-Oct-2021	New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA® (ustekinumab) in Older Patients Across Approved Indications	Janssen
30-Sep-2021	OXURION Announces Positive Results from Part A of Phase 2 Study Evaluating THR-149 for Treatment of Diabetic Macular Edema (DME)	OXURION
30-Sep-2021	LEO Pharma and Veeva Systems Partner for Patient-centric Digital Trials	LEO Pharma
30-Sep-2021	Novartis and Medicines for Malaria Venture report positive results for Phase 2b study of novel ganaplacide/lumefantrine combination in children with malaria	Novartis
29-Sep-2021	£2.7M CHALLENGE SET TO REPLACE USE OF DOGS IN DRUG TESTING	konfer
29-Sep-2021	PureTech Founded Entity Akili Announces Topline Results from Shionogi Phase 2 Study in Japan	PureTech
29-Sep-2021	First participants enrolled in Clinical Trial with Nociceptin/Orphanin peptide receptor (NOP) agonist	Grünenthal
29-Sep-2021	New data reinforce efficacy and convenience of Novartis Cosentyx® (secukinumab) 300 mg autoinjector in adults with psoriasis	Novartis
29-Sep-2021	Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate	Sanofi
29-Sep-2021	Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis that Confirm Ability to Harness the Small Intestinal Axis, SINTAX™, to Treat Systemic Inflammatory Disease	Evelo Biosciences
29-Sep-2021	ReveraGen and Santhera Announce FDA Orphan Grant Funding for Clinical Trial with Vamorolone in Becker Muscular Dystrophy	ReveraGen
28-Sep-2021	Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate	Sanofi
23-Sep-2021	CyPep-1 Shows Preliminary Safety, Tolerability and Early Signs of Efficacy in Part 1 of its Ph I/IIa CICILIA Trial Which Now Moves to Expansion Phase	Cytovation
22-Sep-2021	Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.	Johnson & Johnson
22-Sep-2021	DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder	DemeRx
22-Sep-2021	HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with TUOYI® in the Treatment of Advanced Neuroendocrine Carcinoma in China	HUTCHMED